Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033687 (proteinuria)
 24,015 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

It has been claimed that long-term prednisone treatment ameliorates the course of children with mesangiocapillary glomerulonephritis (MCGN). The International Study of Kidney Disease in Children conducted a randomized, double-blinded, placebo-controlled clinical trial in 80 children with idiopathic MCGN, including 42 patients with type I disease, 14 with type II disease, 17 with type III disease, and 7 with nontypable disease. Criteria for admission included heavy proteinuria and a glomerular filtration rate of greater than or equal to 70 ml/min per 1.73 m2. Prednisone or lactose, 40 mg/m2, was given every other day as a single morning dose. The mean duration of treatment was 41 months, renal failure being the most common reason for termination of therapy. Treatment failure was defined as an increase from baseline of 30% or more in serum creatinine, or more than 35 mumol/l. Overall, treatment failure occurred in 55% of patients treated with lactose, compared with 40% in the prednisone group. Life-table analysis showed a renal survival rate (i.e., stable renal function) at 130 months of 61% among patients receiving prednisone and 12% among patients receiving lactose (P = 0.07). Of patients with type I or III MCGN, 33% treated with prednisone were treatment failures, compared with 58% in the lactose group. Long-term treatment with prednisone appears to improve the outcome of children with MCGN.
 ...
PMID:Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children. 157 Dec 5

Eighteen children with primary MPGN were included in a double blind controlled study. Experimental group received prednisone and control group received lactose. Studies of renal biopsy on admission, at 3 yr (17 pt) and 5 yr (8 pt) were performed. Mean time of observation in both groups was similar (6.5 yr). Four patients of the control group developed ESRD and none of the experimental group. Two patients of the control and one of the experimental group remitted. Serial immunopathological studies showed decreasing mesangial cellularity, thickening of the capillary walls and deposits in both groups. Increase tubulointerstitial alterations and percentage of global sclerotic glomeruli was generally observed except in cases in whom proteinuria disappeared. Our results suggest that prednisone therapy may retard the development of ESRD in children with MPGN. However, longer periods of observation and greater number of cases are necessary to confirm if this treatment in useful.
 ...
PMID:Prednisone versus placebo in membranoproliferative glomerulonephritis: long-term clinicopathological correlations. 388 86